[go: up one dir, main page]

HUP0000651A2 - Konjugátumok prosztatarák kezelésére - Google Patents

Konjugátumok prosztatarák kezelésére

Info

Publication number
HUP0000651A2
HUP0000651A2 HU0000651A HUP0000651A HUP0000651A2 HU P0000651 A2 HUP0000651 A2 HU P0000651A2 HU 0000651 A HU0000651 A HU 0000651A HU P0000651 A HUP0000651 A HU P0000651A HU P0000651 A2 HUP0000651 A2 HU P0000651A2
Authority
HU
Hungary
Prior art keywords
amino acid
active ingredients
cytotoxic agent
subject
acid sequence
Prior art date
Application number
HU0000651A
Other languages
English (en)
Inventor
Deborah Defeo-Jones
Dong-Mei Feng
Victor M. Garsky
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9626309.0A external-priority patent/GB9626309D0/en
Priority claimed from GBGB9718160.6A external-priority patent/GB9718160D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of HUP0000651A2 publication Critical patent/HUP0000651A2/hu
Publication of HUP0000651A3 publication Critical patent/HUP0000651A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

A találmány tárgyát prősztatarák kezelésére adható kőnjűgátűmők vagyezek gyógyászatilag megfelelő sói képezik, amelyek egy őligőpeptidhezkötött citőtőxikűs szert tartalmaznak. A kőnjűgátűmban lévőőligőpeptid őlyan aminősavszekvenciát tartalmaz, amelyet a szabadprősztataspecifikűs antigén szelektív módőn prőteőlitikűsan felszakít,és ahől az őligőpeptidnek a citőtőxikűs szerhez való kapcsőlódásakővalens kötéssel, vagy egy kémiai kapcsőló csőpőrtőn keresztültörténik, és ahől az aminősavszekvenciában legalább egy gyűrűsaminősav van jelen, amely hidrőfil szűbsztitűenst hőrdőz. Akőnjűgátűmban lévő citőtőxikűs szer előnyösen valamely alábbihatóanyagcsőpőrthőz tartőzik: antraciklin hatóanyagők,vinkaalkalőidák, mitőmicinek, bleőmi- cinek, citőtőxikűs nűkleőzidek,pteridin hatóanyagők, diinenszárma-zékők, esztraműsztin,ciklőfőszfamid, taxánők és pődőfillőtőxinők. A találmány tárgyátképezik a fenti kőnjűgátűmőkat tartalmazó gyógyászati készítmények is. ŕ
HU0000651A 1996-10-30 1997-10-27 Conjugates useful in the treatment of prostate cancer HUP0000651A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2922496P 1996-10-30 1996-10-30
GBGB9626309.0A GB9626309D0 (en) 1996-12-18 1996-12-18 Conjugates useful in the treatment of prostate cancer
US4292197P 1997-04-04 1997-04-04
GBGB9718160.6A GB9718160D0 (en) 1997-08-28 1997-08-28 Conjugates useful in the treatment of prostate cancer
PCT/US1997/019225 WO1998018493A2 (en) 1996-10-30 1997-10-27 Conjugates useful in the treatment of prostate cancer

Publications (2)

Publication Number Publication Date
HUP0000651A2 true HUP0000651A2 (hu) 2000-06-28
HUP0000651A3 HUP0000651A3 (en) 2001-12-28

Family

ID=27451580

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0000651A HUP0000651A3 (en) 1996-10-30 1997-10-27 Conjugates useful in the treatment of prostate cancer

Country Status (32)

Country Link
EP (1) EP0942754B1 (hu)
JP (1) JP2000509407A (hu)
KR (1) KR100508199B1 (hu)
AR (1) AR008907A1 (hu)
AT (1) ATE239509T1 (hu)
AU (1) AU726434B2 (hu)
BG (1) BG64768B1 (hu)
BR (1) BR9712589A (hu)
CA (1) CA2268738A1 (hu)
CO (1) CO4930281A1 (hu)
CZ (1) CZ155599A3 (hu)
DE (1) DE69721810T2 (hu)
DK (1) DK0942754T3 (hu)
DZ (1) DZ2333A1 (hu)
EA (1) EA002066B1 (hu)
EE (1) EE03858B1 (hu)
ES (1) ES2196374T3 (hu)
HK (1) HK1024876A1 (hu)
HR (1) HRP970566A2 (hu)
HU (1) HUP0000651A3 (hu)
ID (1) ID21358A (hu)
IL (1) IL129356A0 (hu)
IS (1) IS5025A (hu)
NO (1) NO992069L (hu)
PE (1) PE17399A1 (hu)
PL (1) PL333004A1 (hu)
PT (1) PT942754E (hu)
SK (1) SK57399A3 (hu)
TR (1) TR199901485T2 (hu)
TW (1) TW425286B (hu)
WO (1) WO1998018493A2 (hu)
YU (1) YU21399A (hu)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9815116A (pt) * 1997-12-02 2000-10-10 Merck & Co Inc Conjugado, composição farmacêutica, e, processo para tratar câncer de próstata, e para tratar hiperplasia prostática benigna
CA2238257A1 (en) * 1998-05-22 1999-11-22 Universite De Montreal Endocytosis of amf-r and uses thereof in cancer therapy
JP2002520369A (ja) * 1998-07-17 2002-07-09 アメリカ合衆国 水溶性薬剤およびその製造方法
US6174858B1 (en) 1998-11-17 2001-01-16 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
JP2003518000A (ja) * 1998-12-11 2003-06-03 コールター ファーマシューティカル，インコーポレイティド プロドラッグ化合物およびその調製方法
US6552166B1 (en) 1999-10-19 2003-04-22 Merck & Co., Inc. Process for the preparation of conjugates useful in the treatment of prostate cancer
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
CA2387901A1 (en) * 1999-10-27 2001-05-03 Merck & Co., Inc. Salt form of a conjugate useful in the treatment of prostate cancer
TR200202183T2 (tr) 2000-03-15 2007-01-22 Bristol-Myers Squibb Pharma Company Peptidazla bölünebilen, hedeflenmiş antineoplastik ilaçlar ve terapetik kullanımları
WO2003079972A2 (en) * 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
WO2005035003A2 (en) * 2003-09-22 2005-04-21 Dihedron Corporation Compositions and methods for increasing drug efficiency
CN100372862C (zh) * 2003-11-05 2008-03-05 天津和美生物技术有限公司 具有抗癌活性的阿霉素衍生物及其制备方法和应用
WO2008067495A2 (en) * 2006-11-29 2008-06-05 Rutgers, The State University Of New Jersey Chemotherapeutic conjugates and methods of use
CN101225094A (zh) 2007-01-18 2008-07-23 天津和美生物技术有限公司 具有抗癌活性的蒽醌四环类化合物
AU2010223565B2 (en) * 2009-03-09 2016-06-23 Ktb Tumorforschungsgesellschaft Mbh Prodrugs
EP3138581B1 (en) 2011-03-17 2019-01-02 The University of Birmingham Re-directed immunotherapy
KR20240096553A (ko) 2012-01-12 2024-06-26 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
GB201203442D0 (en) 2012-02-28 2012-04-11 Univ Birmingham Immunotherapeutic molecules and uses
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
EP3253419A1 (en) 2015-02-02 2017-12-13 The University of Birmingham Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes
EP3377103B2 (en) 2015-11-19 2025-03-12 Revitope Limited Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN116635054A (zh) 2020-12-22 2023-08-22 科比欧尔斯公司 包括四肽部分的化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
WO1997014416A1 (en) * 1995-10-18 1997-04-24 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia

Also Published As

Publication number Publication date
DZ2333A1 (fr) 2002-12-28
ATE239509T1 (de) 2003-05-15
CA2268738A1 (en) 1998-05-07
ES2196374T3 (es) 2003-12-16
JP2000509407A (ja) 2000-07-25
PE17399A1 (es) 1999-02-20
TW425286B (en) 2001-03-11
IS5025A (is) 1999-04-13
EP0942754A2 (en) 1999-09-22
ID21358A (id) 1999-05-27
EE03858B1 (et) 2002-10-15
CO4930281A1 (es) 2000-06-27
WO1998018493A3 (en) 1998-07-23
EA199900428A1 (ru) 2000-02-28
NO992069L (no) 1999-06-30
BR9712589A (pt) 1999-10-26
KR20000052970A (ko) 2000-08-25
PL333004A1 (en) 1999-11-08
KR100508199B1 (ko) 2005-08-17
CZ155599A3 (cs) 1999-10-13
EP0942754B1 (en) 2003-05-07
SK57399A3 (en) 2000-01-18
DE69721810D1 (de) 2003-06-12
AR008907A1 (es) 2000-02-23
IL129356A0 (en) 2000-02-17
HUP0000651A3 (en) 2001-12-28
HRP970566A2 (en) 1998-08-31
NO992069D0 (no) 1999-04-29
TR199901485T2 (xx) 1999-08-23
BG103436A (en) 2000-04-28
AU726434B2 (en) 2000-11-09
HK1024876A1 (en) 2000-10-27
WO1998018493A2 (en) 1998-05-07
YU21399A (sh) 2000-03-21
DK0942754T3 (da) 2003-08-04
EA002066B1 (ru) 2001-12-24
DE69721810T2 (de) 2004-03-11
AU5149798A (en) 1998-05-22
EE9900179A (et) 1999-12-15
BG64768B1 (bg) 2006-03-31
PT942754E (pt) 2003-08-29

Similar Documents

Publication Publication Date Title
HUP0000651A2 (hu) Konjugátumok prosztatarák kezelésére
US5021234A (en) Agent and product for the diagnosis and treatment of tumors and for the treatment of weaknesses of the cellular and humoral immune defense
DE69921138D1 (de) Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel
HUP0101545A1 (hu) Peptideket időben elnyújtva kibocsátó gyógyászati készítmények és eljárás az előállításukra
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
HUP0000299A1 (hu) Késleltetett hatóanyag-leadású gyógyszerkészítmények
IL139285A0 (en) Peg-lhrh analog conjugates, their preparation and use
WO2000076551A3 (de) Verfahren zur herstellung einer injizierbaren arzneimittelzubereitung
MY141584A (en) Pharmaceutical uses of bisphosphonates
CA1330378C (en) Amine derivatives of folic acid analogs
HUP0001136A2 (hu) Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények
HUP9801227A2 (hu) Monoamin-oxidáz B inhibitorokból álló gyógyászati készítmények és alkalmazásuk
US5490988A (en) Delivery of therapeutic agents to a target site
BR9510490B1 (pt) composição farmacêutica combinada de dois componentes estruturada para uso em um hospedeiro.
HUP0100012A2 (hu) Makrolid vegyületek alkalmazása rák és a makuláns elváltozások kezelésére
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
AU5691796A (en) Terpenoidic derivatives useful as antitumor agents
EP0745390A3 (en) Polymeric prodrugs for beta-lactamase and uses thereof
MX9805939A (es) Formas solidas de administracion, de liberacion instantanea y procesos para su produccion.
TR200401810T4 (tr) Kısırlık tedavisinde fsh'ın kullanılması
IL117564A0 (en) Pharmaceutical and diagnostic compositions containing lysine derivatives
HUP0104091A2 (hu) Bifunkcionális antitestek és alkalmazásuk tumorellenes szerek célbajuttatására
Wickstrom et al. Future prospects for old chemotherapeutic drugs in the target-specific era; pharmaceutics, combinations, co-drugs and prodrugs with melphalan as an example
NZ335081A (en) Conjugates containing a cytotoxic drug attached via a bond or linker to an oligopeptide comprising at least one cyclic amino acid having a hydrophilic group useful in the treatment of prostate cancer
Le Pape et al. Targetting of immunocompetent cells for tumour scintigraphy